Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-β-activated kinase

Molecular Pharmacology

Volumn 77, Issue 5, 2010, Pages 828-835

  McNeer, Jennifer L ^a   Goussetis, Dennis J ^a   Sassano, Antonella ^a   Dolniak, Blazej ^a   Kroczynska, Barbara ^a   Glaser, Heather ^a   Altman, Jessica K ^a   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 OXOZEAENOL; ARSENIC TRIOXIDE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; THOUSAND AND ONE AMINO ACID KINASE 2; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; COLONY FORMATION; CONTROLLED STUDY; CYTOLYSIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; NEGATIVE FEEDBACK; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLCYSTEINE; ARSENICALS; CELL LINE, TUMOR; DITHIOTHREITOL; ENZYME ACTIVATION; GENETIC VARIATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAP KINASE KINASE KINASES; OXIDES; PHOSPHORYLATION; PROTEIN KINASES; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; TRETINOIN; U937 CELLS;

EID: 77951055592     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.061507     Document Type: Article

References (45)

1. Altman JK, Yoon P, Katsoulidis E, Kroczynska B, Sassano A, Redig AJ, Glaser H, Jordan A, Tallman MS, Hay N, et al. (2008) Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J Biol Chem 283:1992-2001.
2. Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, and Chen SJ (2002) Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol 39:22-26.
3. Chen Z and Cobb MH (2001) Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TAO2. J Biol Chem 276:16070-16075. (Pubitemid 37391645)
4. Chen Z, Hutchison M, and Cobb MH (1999) Isolation of the protein kinase TAO2 and identification of its mitogen-activated protein kinase/extracellular signal-regulated kinase kinase binding domain. J Biol Chem 274:28803-28807. (Pubitemid 129504759)
5. Chen Z, Raman M, Chen L, Lee SF, Gilman AG, and Cobb MH (2003) TAO (thousand- and-one amino acid) protein kinases mediate signaling from carbachol to p38 mitogen-activated protein kinase and ternary complex factors. J Biol Chem 278:22278-22283. (Pubitemid 36830276)
6. Cheung PC, Campbell DG, Nebreda AR, and Cohen P (2003) Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J 22:5793-5805. (Pubitemid 37408818)
7. Choo MK, Kawasaki N, Singhirunnusorn P, Koizumi K, Sato S, Akira S, Saiki I, and Sakurai H (2006) Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol Cancer Ther 5:2970-2976. (Pubitemid 46092038)
8. Dai J, Weinberg RS, Waxman S, and Jing Y (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268-277. (Pubitemid 29019412)
9. Davison K, Mann KK, Waxman S, and Miller WH Jr (2004) JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103:3496-3502. (Pubitemid 38525683)
10. Dermime S, Grignani F, Clerici M, Nervi C, Sozzi G, Talamo GP, Marchesi E, Formelli F, Parmiani G, and Pelicci PG (1993) Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein. Blood 82:1573-1577. (Pubitemid 23263975)
11. Dhillon AS, Hagan S, Rath O, and Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279-3290. (Pubitemid 46763021)
12. Dolniak B, Katsoulidis E, Carayol N, Altman JK, Redig AJ, Tallman MS, Ueda T, Watanabe-Fukunaga R, Fukunaga R, and Platanias LC (2008) Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem 283:12034-12042.
13. Douer D and Tallman MS (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396-2410. (Pubitemid 46218734)
14. Evens AM, Lecane P, Magda D, Prachand S, Singhal S, Nelson J, Miller RA, Gartenhaus RB, and Gordon LI (2005) Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 105:1265-1273. (Pubitemid 40170902)
15. Frazier DP, Wilson A, Dougherty CJ, Li H, Bishopric NH, and Webster KA (2007) PKC-alpha and TAK-1 are intermediates in the activation of c-Jun NH2-terminal kinase by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 292:H1675-H1684. (Pubitemid 46572384)
16. Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, Nebreda AR, Davis RJ, and Platanias LC (2006) Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 66:6763-6771. (Pubitemid 44085635)
17. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, Matsumoto K, and Nishida E (1999) Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem 274:27161-27167. (Pubitemid 129520243)
18. Huangfu WC, Omori E, Akira S, Matsumoto K, and Ninomiya-Tsuji J (2006) Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-mediated NF-kappaB activation: TAO2 regulates TAK1 pathways. J Biol Chem 281:28802-28810. (Pubitemid 44507023)
19. Inagaki M, Omori E, Kim JY, Komatsu Y, Scott G, Ray MK, Yamada G, Matsumoto K, Mishina Y, and Ninomiya-Tsuji J (2008) TAK1-binding protein 1, TAB1, mediates osmotic stress-induced TAK1 activation but is dispensable for TAK1-mediated cytokine signaling. J Biol Chem 283:33080-33086.
20. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, and Waxman S (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102-2111. (Pubitemid 29430427)
21. Kannan-Thulasiraman P, Katsoulidis E, Tallman MS, Arthur JS, and Platanias LC (2006) Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide. J Biol Chem 281:22446-22452. (Pubitemid 44242273)
22. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, and Deeg HJ (2005) NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 106:3917-3925. (Pubitemid 41739032)
23. Kroczynska B, Kaur S, Katsoulidis E, Majchrzak-Kita B, Sassano A, Kozma SC, Fish EN, and Platanias LC (2009) Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals. Mol Cell Biol 29:2865-2875.
24. Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, and Nicot C (2001) Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 98:3762-3769.
25. Mann KK, Padovani AM, Guo Q, Colosimo AL, Lee HY, Kurie JM, and Miller WH Jr (2005) Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation. J Clin Invest 115:2924-2933. (Pubitemid 41434420)
26. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, and Dorken B (2003) Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 102:1028-1034. (Pubitemid 36917800)
27. Miller WH Jr., Schipper HM, Lee JS, Singer J, and Waxman S (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62:3893-3903.
28. Moriguchi T, Kuroyanagi N, Yamaguchi K, Gotoh Y, Irie K, Kano T, Shirakabe K, Muro Y, Shibuya H, Matsumoto K, et al. (1996) A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J Biol Chem 271:13675-13679. (Pubitemid 26187979)
29. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, Shiina M, Mihara M, Tsuchiya M, and Matsumoto K (2003) A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 278:18485-18490. (Pubitemid 36799472)
30. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, and Matsumoto K (1999) The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398:252-256. (Pubitemid 29142861)
31. O'Dwyer ME, La Rosee P, Nimmanapalli R, Bhalla KN, and Druker BJ (2002) Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Semin Hematol 39:18-21.
32. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, and Lee YY (2000) Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60:3065-3071.
33. Platanias LC (2009) Biological responses to arsenic compounds. J Biol Chem 284:18583-18587.
34. Raman M, Earnest S, Zhang K, Zhao Y, and Cobb MH (2007) TAO kinases mediate activation of p38 in response to DNA damage. EMBO J 26:2005-2014. (Pubitemid 46625802)
35. Sakurai H, Shigemori N, Hasegawa K, and Sugita T (1998) TGF-beta-activated kinase 1 stimulates NF-kappa B activation by an NF-kappa B-inducing kinase-independent mechanism. Biochem Biophys Res Commun 243:545-549. (Pubitemid 28414061)
36. Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, Tallman MS, and Platanias LC (2007) Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 67:4524-4532. (Pubitemid 46815104)
37. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, et al. (2005) TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 19:2668-2681. (Pubitemid 41627934)
38. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K, and Gaynor RB (2003) TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J Mol Biol 326:105-115. (Pubitemid 36279361)
39. Uddin S, Yenush L, Sun XJ, Sweet ME, White MF, and Platanias LC (1995) Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′-kinase. J Biol Chem 270:15938-15941.
40. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, and Platanias LC (2002) Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 277:44988-44995. (Pubitemid 36159097)
41. Wang ZG, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP Jr, and Pandolfi PP (1998) Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92:1497-1504. (Pubitemid 28406851)
42. Wei LH, Lai KP, Chen CA, Cheng CH, Huang YJ, Chou CH, Kuo ML, and Hsieh CY (2005) Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB. Oncogene 24:390-398.
43. Wen J, Cheng HY, Feng Y, Rice L, Liu S, Mo A, Huang J, Zu Y, Ballon DJ, and Chang CC (2008) p38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 140:169-180. (Pubitemid 350265041)
44. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, and Matsumoto K (1995) Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270:2008-2011. (Pubitemid 26097194)
45. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, et al. (1999) Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 91:772-778. (Pubitemid 29239056)